From a cellular pharmacy viewpoint, Relafen 750 represents a compelling case study. Its mechanism of action involves the preferential inhibition of cyclooxygenase enzymes, specifically those catalysts, although with a measure of lack of specificity compared to newer agents. This leads to a lessening of prostaglandin synthesis, ultimately diminis… Read More